Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Biologics have revolutionized moderate-to-severe atopic dermatitis (AD) treatment since dupilumab's 2017 approval, with three more FDA-approved agents now available. Experts say these targeted therapies have dramatically improved patient quality of life — from better sleep to returning to work — but still only clear 40–60% of patients. Insurance hurdles and the need for long-term therapy remain key challenges.
Since dupilumab (Dupixent) was approved in 2017, biologics have fundamentally changed how dermatologists treat moderate-to-severe atopic dermatitis (AD). Three additional biologics — tralokinumab (2021), lebrikizumab (2024), and nemolizumab (2024) — have since joined the armamentarium. Unlike older systemic therapies borrowed from other diseases (cyclosporine, methotrexate, systemic steroids), these agents selectively target overactivated immune pathways rather than broadly suppressing the immune system, offering better efficacy with fewer side effects.
The real-world impact on patients has been profound. Experts describe patients sleeping through the night, returning to work, and reclaiming daily life — outcomes that go far beyond skin clearance. Still, biologics aren't perfect: current agents achieve complete or near-complete clearance in only 40–60% of patients, leaving room for innovation. Managing partial or waning responses often involves adding topical agents, switching biologics, or adjusting dosing intervals. Insurance barriers, prior authorizations, and step therapy requirements remain significant obstacles for both patients and providers.
Key Takeaways:
Why it matters: Biologics have set a new standard of care for AD, but gaps in efficacy and access mean the work isn't done. With a robust pipeline and a growing understanding of AD biology, the field is entering what experts call a "virtuous cycle" — where better treatments deepen disease understanding, which in turn drives even better therapies.
